Abstract
B-cell chronic lymphocytic leukaemia (B-CLL) cells express low levels of co-stimulatory molecules and therefore fail to induce activation and differentiation of tumour-specific T cells. We have shown that patients with B-CLL have considerably expanded numbers of cytomegalovirus (CMV) reactive CD8+ T cells. This study demonstrated that B-CLL cells loaded with CMV peptide not only promoted the ex vivo expansion of autologous, in vivo-generated virus-specific T cells, but also constituted excellent target cells for these cytotoxic T cells, even without ex vivo re-stimulation. Directing virus-specific T cells to B-CLL may overcome the inadequate immunostimulatory capacity of these cells, which could be exploited for T-cell mediated immunotherapy.
Author supplied keywords
Cite
CITATION STYLE
Kater, A. P., Remmerswaal, E. B. M., Nolte, M. A., Eldering, E., Van Oers, M. H. J., & Van Lier, R. A. W. (2004). Autologous cytomegalovirus-specific T cell as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. British Journal of Haematology, 126(4), 512–516. https://doi.org/10.1111/j.1365-2141.2004.05070.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.